Clinical trials: Influenza Infection
Influenza, Human
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with…
- Trial name
- ZX-7101A-203 (NCT05711797)
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults
The aim of the study is to assess the safety profile of a quadrivalent influenza vaccine (QIV) and to demonstrate that 3 different industrial lots of QIV induce an equivalent immune response in children/adolescents (9 to 17 years…
- Trial name
- NCT01481454
- Testing
- Quadrivalent Influenza Vaccine (split virion, inactivated), 2011 to 2012 Trivalent Influenza Vaccine
- Where
- 6 sites in Australia, Philippines
- Volunteers
- 1,701 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00346723
- Testing
- Influvac® subunit influenza vaccine for i.m./deep s.c.injection
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.
- Trial name
- NCT05569239
- Testing
- OVX836 480µg, Saline Solution
- Where
- 16 sites in Belgium, Finland and 2 more
- Volunteers
- 2,891 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)
The objective of this study is to assess the safety, tolerability and immunogenicity of a Split Virus, Vero Cell derived, Seasonal Influenza Vaccine (VCIV) in comparison to a Licensed Egg Derived, Split Virus, Seasonal Influenza…
- Trial name
- NCT00424086
- Testing
- Inactivated seasonal influenza vaccine (split virus, vero cell derived), Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the…
- Trial name
- VAP00007 (NCT04460781)
- Testing
- Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
- Where
- United States
- Volunteers
- 96,175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate an Influenza Vaccine Candidate
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the…
- Trial name
- NCT00540228
- Testing
- Influenza Vaccine GSK1247446A - 4 different formulations, Fluarix™
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 1,006 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adults
A Study to Learn About mRNA Vaccines Against Influenza in Adults
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza…
- Trial name
- NCT07431853
- Testing
- Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3
- Where
- 15 sites in United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or without Matrix-M1 adjuvant in healthy adults ≥ 65…
- Trial name
- NCT03658629
- Testing
- NanoFlu (Quad-NIV), Matrix-M Adjuvant, Fluzone HD
- Where
- 14 sites in United States
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Orthomyxoviridae Infections
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine
This study is designed to generate clinical data as outlined in the Note for Guidance on harmonization requirements for influenza vaccine marketing authorization by the European Medicines Agency.
- Trial name
- NCT00343681
- Testing
- Inactivated influenza vaccine (split virion)
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Tract Infections, Influenza, Human
Idylla IFV-RSV Panel Clinical Testing
This clinical study will collect fresh samples and perform laboratory testing on fresh and archived samples as described in the protocol.
- Conditions
- Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
- Trial name
- RP1 (NCT02786381)
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Influenza
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT06779981
- Testing
- Nasopharyngeal swabs
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2010/2011
The purpose of the study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season for yearly licensing application.
- Trial name
- NCT01157702
- Testing
- Inactivated influenza vaccine (split virus, Vero cell-derived)
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.
- Trial name
- NCT01310400
- Testing
- Inflexal V, Agrippal
- Where
- China
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the…
- Trial name
- NCT00395174
- Testing
- Influenza Vaccination
- Where
- 7 sites in United States
- Volunteers
- 870 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial…
- Trial name
- NCT05972174
- Testing
- mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza Immunization
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of…
- Trial name
- NCT05829356
- Testing
- H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4)
- Where
- 8 sites in Australia, United Kingdom
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company